Literature DB >> 21655948

Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease.

W Nseir1, A Shalata, A Marmor, N Assy.   

Abstract

The most common cause of death in patients with nonalcoholic fatty liver disease (NAFLD) is coronary artery disease (CAD), not chronic liver disease. Fatty liver increases cardiovascular risk by classical (dyslipidemia, hypertension, diabetes) and by less conventional mechanisms. Common pathways involved in the pathogenesis of fatty liver and CAD includes hepatic insulin resistance and sub clinical inflammation. The hepatic insulin resistance state of fatty liver infiltration is characterized by increased FFA, which causes lipotoxicity and impairs endothelium-dependent vasodilatation, increases oxidative stress, and has a cardio toxic effect. Additional metabolic risk factors include leptin, adiponectin, pro inflammatory cytokines [such as IL-6, C-reactive protein and plasminogen activator inhibitor-1 (PAI-1)], which together lead to increased oxidative stress and endothelial dysfunction, finally promoting coronary artery disease (CAD). When classical risk factors are superimposed on fatty liver accumulation, they may further increase the new metabolic risk factors, exacerbating CAD. The clinical implication is that patients with NAFLD are at higher risk (steatohepatitis, diabetes, obesity, atherogenic dyslipidemia) and should undergo periodic cardiovascular risk assessment including the Framingham score, cardiac effort test, and measurement of intimae-media thickening of the carotids arteries. This may improve risk stratification for CAD.

Entities:  

Mesh:

Year:  2011        PMID: 21655948     DOI: 10.1007/s10620-011-1767-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  114 in total

Review 1.  Nonalcoholic fatty liver disease: an agenda for clinical research.

Authors:  Zobair M Younossi; Anna Mae Diehl; Janus P Ong
Journal:  Hepatology       Date:  2002-04       Impact factor: 17.425

Review 2.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Christopher P Day; Enzo Bonora
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

3.  Statins and hepatic steatosis: perspectives from the Dallas Heart Study.

Authors:  Jeffrey D Browning
Journal:  Hepatology       Date:  2006-08       Impact factor: 17.425

4.  Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.

Authors:  Giovanni Targher; Lorenzo Bertolini; Felice Poli; Stefano Rodella; Luca Scala; Roberto Tessari; Luciano Zenari; Giancarlo Falezza
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

5.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

6.  Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study.

Authors:  Douglas S Lee; Jane C Evans; Sander J Robins; Peter W Wilson; Irene Albano; Caroline S Fox; Thomas J Wang; Emelia J Benjamin; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-11-09       Impact factor: 8.311

7.  Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis.

Authors:  Shiro Yokohama; Masashi Yoneda; Masakazu Haneda; Satoshi Okamoto; Mituyoshi Okada; Kazunobu Aso; Takenao Hasegawa; Yoshihiko Tokusashi; Naoyuki Miyokawa; Kimihide Nakamura
Journal:  Hepatology       Date:  2004-11       Impact factor: 17.425

8.  C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis.

Authors:  Sridevi Devaraj; Dan Yan Xu; Ishwarlal Jialal
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

9.  Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

Authors:  Masahide Hamaguchi; Takao Kojima; Noriyuki Takeda; Chisato Nagata; Jun Takeda; Hiroshi Sarui; Yutaka Kawahito; Naohisa Yoshida; Atsushi Suetsugu; Takahiro Kato; Junichi Okuda; Kazunori Ida; Toshikazu Yoshikawa
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

10.  Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.

Authors:  H B Hubert; M Feinleib; P M McNamara; W P Castelli
Journal:  Circulation       Date:  1983-05       Impact factor: 29.690

View more
  31 in total

1.  Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease.

Authors:  Michael S Kostapanos; Vasilios G Athyros; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Dig Dis Sci       Date:  2012-02-07       Impact factor: 3.199

2.  Triglycerides Mediate Body Mass Index and Nonalcoholic Fatty Liver Disease: A Population-Based Study.

Authors:  Jie Xing; Xue Guan; Qian Zhang; Shuohua Chen; Shouling Wu; Xiujing Sun
Journal:  Obes Facts       Date:  2021-03-29       Impact factor: 3.942

3.  SNPs affecting serum metabolomic traits may regulate gene transcription and lipid accumulation in the liver.

Authors:  Snezana Mirkov; Jamie L Myers; Jacqueline Ramírez; Wanqing Liu
Journal:  Metabolism       Date:  2012-06-26       Impact factor: 8.694

Review 4.  Nonalcoholic fatty liver disease: implications for cardiovascular risk.

Authors:  Amreen Dinani; Arun Sanyal
Journal:  Cardiovasc Endocrinol       Date:  2017-05-17

Review 5.  Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies.

Authors:  William Nseir; Julnar Mograbi; Murad Ghali
Journal:  Dig Dis Sci       Date:  2012-03-15       Impact factor: 3.199

Review 6.  Dyslipidemia in patients with nonalcoholic fatty liver disease.

Authors:  Hemant Chatrath; Raj Vuppalanchi; Naga Chalasani
Journal:  Semin Liver Dis       Date:  2012-03-13       Impact factor: 6.115

Review 7.  Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review.

Authors:  William Nseir; Mahmud Mahamid
Journal:  Curr Atheroscler Rep       Date:  2013-03       Impact factor: 5.113

8.  The ERLIN1-CHUK-CWF19L1 gene cluster influences liver fat deposition and hepatic inflammation in the NHLBI Family Heart Study.

Authors:  Mary F Feitosa; Mary K Wojczynski; Kari E North; Qunyuan Zhang; Michael A Province; Jeffrey J Carr; Ingrid B Borecki
Journal:  Atherosclerosis       Date:  2013-02-18       Impact factor: 5.162

Review 9.  Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis.

Authors:  Licia Polimeni; Maria Del Ben; Francesco Baratta; Ludovica Perri; Fabiana Albanese; Daniele Pastori; Francesco Violi; Francesco Angelico
Journal:  World J Hepatol       Date:  2015-06-08

10.  Sex-influenced association of nonalcoholic fatty liver disease with coronary heart disease.

Authors:  Mary F Feitosa; Alexander P Reiner; Mary K Wojczynski; Mariaelisa Graff; Kari E North; Jeffrey J Carr; Ingrid B Borecki
Journal:  Atherosclerosis       Date:  2013-01-25       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.